{"filing":{"accession_number":"0001193125-26-264916","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"cgem-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm"},"events":[{"id":5638,"run_id":4941,"accession_number":"0001193125-26-264916","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Cullinan Therapeutics disclosed updated Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, along with initial Phase 1b/2a data for velinotamig in SLE, demonstrating positive efficacy and safety signals including clinical remission in RA patients and rapid improvements in SLE biomarkers. This clinical progress represents material advancement of the company's pipeline that would affect a reasonable investor's assessment of the company's valuation and strategic direction.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5716,"accession_number":"0001193125-26-264916","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces updated Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, plus initial Phase 1b/2a data for velinotamig in SLE. While clinical trial data updates are material to investors evaluating a biopharmaceutical company's pipeline progress, this does not fit neatly into the standard taxonomy categories (not an earnings release, not a specific regulatory event like restatement or auditor change). The materiality stems from the advancement of clinical programs that could affect the company's valuation and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:33:09.603853+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5717,"accession_number":"0001193125-26-264916","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports interim clinical trial data from Phase 1 studies of two drug candidates (CLN-978 and velinotamig) showing positive efficacy and safety signals in autoimmune diseases. While the data is preliminary and subject to change, the achievement of clinical remission in RA patients and rapid improvements in SLE patients' SLEDAI-2K scores and proteinuria represent material clinical progress that would affect a reasonable investor's assessment of the company's pipeline prospects. This does not fit neatly into earnings_release (no financial results) or other specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:33:09.603853+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5716,"accession_number":"0001193125-26-264916","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces updated Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, plus initial Phase 1b/2a data for velinotamig in SLE. While clinical trial data updates are material to investors evaluating a biopharmaceutical company's pipeline progress, this does not fit neatly into the standard taxonomy categories (not an earnings release, not a specific regulatory event like restatement or auditor change). The materiality stems from the advancement of clinical programs that could affect the company's valuation and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:33:09.603853+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-10"},{"id":5717,"accession_number":"0001193125-26-264916","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports interim clinical trial data from Phase 1 studies of two drug candidates (CLN-978 and velinotamig) showing positive efficacy and safety signals in autoimmune diseases. While the data is preliminary and subject to change, the achievement of clinical remission in RA patients and rapid improvements in SLE patients' SLEDAI-2K scores and proteinuria represent material clinical progress that would affect a reasonable investor's assessment of the company's pipeline prospects. This does not fit neatly into earnings_release (no financial results) or other specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:33:09.603853+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-06-10"}]}